Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE: HRT vs COCs in Premature Ovarian Insufficiency
NCT02922348Phase 3Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Mar 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of estradiol, progesterone, ethinyl estradiol and norgestimate in primary ovarian insufficiency (POI) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Recruitment at 1 year. Planned start Mar 2016; status: withdrawn.
02
Drugs
estradiolprogesteroneethinyl estradiolnorgestimate
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT02922348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922348.